Actemra/RoActemra approved by the European Commission to treat patients with severe COVID-19

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has extended the marketing authorisation for Actemra®/RoActemra® (tocilizumab) to include the treatment of COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.1 This ...

Related Keywords

Ghana ,Australia ,Japan ,United States ,Canada ,United Kingdom ,Switzerland ,Australian ,American ,Levi Garraway ,Actemra Roactemra ,Chugai Pharmaceutical Co Ltd ,Genentech ,Gilead Sciences Inc ,European Union ,Committee For Medicinal Products Human Use ,University Of Oxford ,University Of Oxford Randomised Evaluation ,European Commission ,Drug Administration ,World Health Organization ,Head Of Global Product Development ,Journal Of The American Medical Association ,Australian Therapeutic Goods Administration ,Approval Of Roche Products Pty Ltd ,Roche Group ,European Medicines Agency ,Medicinal Products ,Human Use ,Chief Medical Officer ,Global Product ,Randomised Evaluation ,Evaluating Minority Patients ,Gilead Sciences ,American Medical Association ,Japan Actemra ,Emergency Use Authorization ,World Health Organization Model Lists ,Essential Medicines ,Dow Jones Sustainability Indices ,Chugai Pharmaceutical ,Roactemra Summary ,Therapeutic Goods ,Provisional Approval ,Roche Products Pty Ltd ,